Vaccine Co. Secures European Regulatory Breakthrough Potential
Source: Dr. Jonathan Aschoff (07/07/2025)
GeoVax Labs Inc. (GOVX:NASDAQ) recently raised US$6 million, projected to find operations through the last quarter of 2025, according to a ROTH Capital Markets research note. The company also received highly favorable guidance for GEO-MVA, its prophylactic vaccine for Mpox and smallpox from The European Medicines Agency.
read more >
Biotech Co. Still a Buy Despite Manufacturing Setbacks
Source: Emily Bodnar (07/07/2025)
While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note.
read more >
Biotech Firm Adjusts Placement Terms to Fuel U.S. Expansion
Source: Streetwise Reports (07/07/2025)
Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out.
read more >
Biotech Company Finds DNA-Targeting Drugs with AI in Canada
Source: Streetwise Reports (07/02/2025)
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) shared AGM results and key AI-driven cancer drug milestones in Vancouver. Read why some analysts are seeing a 300% potential return
read more >
Analyst Has Confidence in Biotech's Path
Source: Dr. Joseph Pantginis (06/26/2025)
Vertex Pharmaceuticals Inc.'s (VRTX:NASDAQ) updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note.
read more >